BC Innovations | Apr 22, 2019
Distillery Therapeutics

Inhibiting the LLGL2-SLC7A5-YKT6 complex for breast cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting the LLGL2-SLC7A5-YKT6 leucine transporter complex could help treat breast cancer. In patients with estrogen receptor- and progesterone receptor-positive breast cancer,...
BC Innovations | Jan 17, 2018
Distillery Therapeutics


INDICATION: Neuroendocrine tumors; lymphoma Cell culture and mouse studies suggest inhibiting SLC7A5 or SLC43A1 could help treat MYC-driven neuroblastoma and Burkitt’s lymphoma. In MYC-driven human neuroblastoma and Burkitt’s lymphoma cell lines, shRNA targeting SLC7A5 or...
BC Week In Review | Feb 3, 2017
Company News

Therapeia, Telix deal

Therapeia granted Telix rights to ACD-101 to treat glioblastoma and an exclusive option to acquire Therapeia, which Telix plans to exercise in 2Q17. Telix said it expects the synthetic amino acid that targets solute carrier...
Items per page:
1 - 3 of 3